COMMUNIQUÉS West-GlobeNewswire

Amarin Reports Second Quarter 2025 Financial Results
30/07/2025
-- European Partnership with Recordati Established to Maximize VAZKEPA ® in Europe; Global Corporate Restructuring Implemented with Anticipated $70 Million in Operating Expense Savings Over Next 12 Months -- -- Q2 2025 [...]
Novasight™ Hybrid Imaging System Featured in Published JSCAI Case Report Demonstrating Superior Diagnosis and Precision-Guided Therapy in Complex Coronary Case
30/07/2025
TORONTO, July 30, 2025 (GLOBE NEWSWIRE) -- Conavi Medical Inc. (TSXV: CNVI) (OTCQB: CNVIF), a leader in hybrid intravascular imaging, is pleased to announce the publication of a compelling case report in the Journal of [...]
BioStem Technologies to Host Second Quarter 2025 Financial Results Conference Call on August 14, 2025
30/07/2025
Conference call and webcast to be held at 4:30 PM ET POMPANO BEACH, Fla., July 30, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacture, and [...]
Avacta to Present New FAP Dox (AVA6000) Data at the European Society for Medical Oncology (ESMO) Congress
30/07/2025
LONDON and PHILADELPHIA, July 30, 2025 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, ‘the Company’), a life sciences company developing innovative, targeted oncology drugs, today announces that the Company will [...]
Teva's Innovative Portfolio Fuels 10th Consecutive Quarter of Growth in Q2 2025; Increases 2025 Revenue Outlook for Key Innovative Products and EPS, and Reaffirms All Other Components
30/07/2025
On track for 30% operating profit margin by 2027 in line with our Pivot to Growth Strategy. Q2 2025 shows 10 th consecutive quarter of year-over-year (YoY) revenue growth; Revenues of $4.2 billion, +1% in local [...]
Celcuity Inc. Announces Pricing of Concurrent Public Offerings of 2.750% Convertible Senior Notes Due 2031 and Common Stock and Pre-Funded Warrants
30/07/2025
MINNEAPOLIS, July 30, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC) (the “Company”), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the pricing of [...]
Madrigal Pharmaceuticals Enters into Exclusive Global License Agreement for Oral GLP-1 Receptor Agonist with CSPC Pharmaceutical Group Limited
30/07/2025
License agreement supports Madrigal’s pipeline strategy to develop innovative combination treatments for MASH, anchored by its foundational therapy Rezdiffra™ (resmetirom) Combining Rezdiffra with the oral GLP-1, [...]
KFSHRC Advances Robotic Surgery with a Successful Ivor Lewis Esophagectomy
30/07/2025
RIYADH, Saudi Arabia, July 30, 2025 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital and Research Centre (KFSHRC) in Riyadh successfully performed a robotic Ivor Lewis esophagectomy, the first of its kind in the [...]
Dr. Falk Pharma and Allianthera (Suzhou) Biopharmaceuticals Forge Strategic Partnership for Novel AhR Agonist Development
30/07/2025
Freiburg (Germany), Suzhou (China) and Boston (USA), July 30, 2025: Dr. Falk Pharma GmbH and Allianthera (Suzhou) Biopharmaceuticals Co., Ltd. Announce Strategic Partnership to Develop a Novel AhR Agonist for the [...]
Rakovina Therapeutics Highlights Long-Standing Collaboration with the University of British Columbia and the Vancouver Prostate Centre
30/07/2025
VANCOUVER, British Columbia, July 30, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing cancer therapies through AI-powered [...]
Leading European Shipbuilder Selects Aino’s SaaS Platform
30/07/2025
Aino Health AB (publ) has signed an agreement with one of Europe’s leading shipbuilding companies for the implementation of the Aino SaaS platform. The agreement covers 2,000 employees and aims to strengthen the [...]
AB Science receives regulatory approval from European countries to initiate third stage of Phase I/II study combining its molecule AB8939 with venetoclax for the treatment of AML
30/07/2025
PRESS RELEASE AB SCIENCE RECEIVES REGULATORY APPROVAL FROM EUROPEAN COUNTRIES TO INITIATE THIRD STAGE OF PHASE I/II STUDY COMBINING ITS MOLECULE AB8939 WITH VENETOCLAX FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA THE [...]
AB Science a reçu l’approbation règlementaire de pays européens pour initier la troisième étape de la phase I/II visant à combiner sa molécule AB8939 avec le venetoclax dans le traitement de la LMA
30/07/2025
COMMUNIQUÉ DE PRESSE AB SCIENCE A RECU L’APPROBATION REGLEMENTAIRE DE PAYS EUROPEENS POUR INITIER LA TROISIEME ETAPE DE LA PHASE I/II VISANT A COMBINER SA MOLÉCULE AB8939 AVEC LE VENETOCLAX DANS LE TRAITEMENT DE LA [...]
Sandoz signs non-binding term sheet with Evotec SE to acquire its Just-Evotec Biologics in-house development and manufacturing capabilities in Toulouse, France
30/07/2025
Ad-hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Proposed transaction would seamlessly align with Sandoz strategic objective of capitalizing on projected USD 300 billion biosimilar [...]
Clenbuterol for Sale: The Complete Guide to Buying Real Clen Pills Online Without Getting Scammed
30/07/2025
Clenbuterol for Sale: Where to Buy Real Clen Pills Online Without Risking Your Health or Wallet In recent years, Clenbuterol has surged in popularity among athletes and bodybuilders looking for an effective way to shed [...]
Press Release: Sanofi’s SAR446523, a GPRC5D monoclonal antibody, earns orphan drug designation in the US for multiple myeloma
30/07/2025
Sanofi’s SAR446523, a GPRC5D monoclonal antibody, earns orphan drug designation in the US for multiple myeloma Designation granted for IgG1-based GPRC5D monoclonal antibody for the potential treatment of patients with [...]
Communiqué de presse: Le SAR446523 de Sanofi, un anticorps monoclonal anti-GPRC5D, se voit accorder la désignation médicament orphelin pour le myélome multiple aux États-Unis
30/07/2025
Le SAR446523 de Sanofi, un anticorps monoclonal anti-GPRC5D, se voit accorder la désignation médicament orphelin pour le myélome multiple aux États-Unis Désignation accordée pour l’anticorps monoclonal GPRC5D à base d’ [...]
Strong sales acceleration of QUVIVIQ drives Idorsia toward profitability – H1 2025 results
30/07/2025
Ad hoc announcement pursuant to Art. 53 LR QUVIVIQ™ (daridorexant): Strong performance and sales acceleration with total net sales of CHF 58 million in H1 2025 and increase of 145% compared to the same period in 2024, [...]
Larimar Therapeutics Announces Pricing of Underwritten Public Offering
30/07/2025
BALA CYNWYD, Pa., July 29, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today [...]

Pages